The Blood Grouping Reagents Market in China has demonstrated consistent growth over the past several years. In 2023, the market size per capita was 0.25 USD. Forecasts indicate a year-on-year growth from 2024 to 2028, with values rising from 0.26 USD in 2024 to 0.3 USD by 2028. This reflects a steady increase in market size, influenced by improvements in healthcare infrastructure, increased awareness, and better diagnostic practices.
Year-on-year percentage variations show an approximate consistent annual growth rate of 3.85% from 2023 to 2024 and from 2024 to 2025, continuing similarly through to 2028. The CAGR over the five-year period from 2023 to 2028 is about 3.85%, illustrating a stable upward trend.
Future trends to watch for include advancements in diagnostic technologies, increased healthcare investments, and potential regulatory changes that could enhance market growth. Additionally, population aging and higher prevalence of chronic diseases could further drive demand for blood grouping reagents in China.
